Kolexia
Gilles Laurence Pharmacien
Gilles Laurence
Pharmacien
Centre Léon-Bérard
Lyon, France
27 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Sarcomes Sarcome synovial Tumeurs du sein Carcinome canalaire du sein Tumeurs colorectales Maladie iatrogène Carcinome lobulaire Lymphopénie Troubles du rythme cardiaque

Collaborateurs

Voir plus
Perol David
Perol David
Centre Léon-Bérard, Lyon, France
Cassier Philippe
Cassier Philippe
Centre Léon-Bérard, Lyon, France
Blay Jean Yves
Blay Jean Yves
Centre Léon-Bérard, Lyon, France
Terret Catherine
Terret Catherine
Centre Léon-Bérard, Lyon, France

Industries

Voir plus
Baxter
1 collaboration(s)
Dernière en 2017
Roche
1 collaboration(s)
Dernière en 2017
{{person.topindus3.name}}
{{person.topindus3.tot}} collaboration(s)
Dernière en {{person.topindus3.last}}
{{person.topindus4.name}}
{{person.topindus4.tot}} collaboration(s)
Dernière en {{person.topindus4.last}}

Dernières activités

Voir plus
480P CATRIPCA – A phase I of pembrolizumab (P) combined with Xevinapant (Debio 1143, (X)) in patients (pts) with non MSI-high advanced/metastatic pancreatic ductal adenocarcinoma (PDAC) or colorectal cancer (CRC)
Abstract Book of the ESMO Congress 2022, 9 - 13 September 2022   01 septembre 2022
ELYPSE-7: a randomized placebo-controlled phase IIa trial with CYT107 exploring the restoration of CD4+ lymphocyte count in lymphopenic metastatic breast cancer patients.
Annals of oncology : official journal of the European Society for Medical Oncology   09 mars 2022
Identification and characterization of a new soybean promoter induced by Phakopsora pachyrhizi, the causal agent of Asian soybean rust.
BMC biotechnology   25 mars 2021
External contamination of antineoplastic drug vials: an occupational risk to consider.
European journal of hospital pharmacy : science and practice   25 septembre 2020
A first in human, phase I trial of NP137, a first-in-class antibody targeting netrin-1, in patients with advanced refractory solid tumors
Abstract Book of the 44th ESMO Congress (ESMO 2019) 27 September – 1 October 2019, Barcelona, Spain   01 octobre 2019
Medication errors in Auvergne-Rhône-Alpes: A prospective pilot study led in collaboration by regional vigilance and support structures.
Therapie   26 juillet 2019
A phase I dose escalation trial evaluating the impact of an in situ immunization strategy with intra-tumoral injections of Pexa-Vec in combination with ipilimumab in advanced solid tumors with injectable lesions
Abstract Book of ESMO Immuno-Oncology Congress 2018 13–16 December, Geneva, Switzerland   01 décembre 2018
A first-in-human study investigating biodistribution, safety and recommended dose of a new radiolabeled MAb targeting FZD10 in metastatic synovial sarcoma patients.
BMC cancer   08 juin 2018
SYNFRIZZ: First in Man Study Investigating the Biodistribution, the Safety and Optimal Recommended Dose of a New Radiolabelled Monoclonal Antibody Targeting Frizzled Homolog 10 (FZD10) in Patients With Relapsed or Refractory Non Resectable Synovial Sarcomas
Essai Clinique (OncoTherapy Science, Inc.)   16 mai 2017
Risk stratification of arrhythmia and death in ARVC
Printemps de la Cardiologie : Recherche Fondamentale et Clinique 2017   01 avril 2017